OFF O 4 2006 BY

PTO/SB/08a (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
duction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO 10/594,707 **Application Number** September 28, 2006 Filing Date INFORMATION DISCLOSURE First Named Inventor OHARA et al. STATEMENT BY APPLICANT Art Unit (Use as many sheets as necessary) **Examiner Name** 2 Attorney Docket Number 3190-100 Sheet

U.S. PATENT DOCUMENTS						
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Initials*	Cite No.1	Number - Kind Code ^{2 (if known)}	MM-DD-YYYY	Applicant of Cited Document	Figures Appear	
<u> </u>		US-				
		US-				
		US-				
	1	US-				
		US-				
***************************************	-	US-				
	İ	US-				
***************************************		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-		**************************************		
***************************************	<u> </u>	US-				
		US-				

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т°
		WO 00/12711 A1	03-09-2000	Incyte Pharmaceuticals Inc.		

		 _
Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

U nd	er the Paperwork Reduction Act	of 1995,	no persons are	U.S. Patent a required to respond to a collection of	PTO/SB/08b (09-06) Approved for use through 03/31/2007. OMB 0651-0031 nd Trademark Office; U.S. DEPARTMENT OF COMMERCE of information unless it displays a valid OMB control number.	
Substitu	te for form 1449B/PTO	<u>-</u>		Complete if Known		
••••				Application Number	10/594,707	
INFORMATION DISCLOSURE			SURF	Filing Date	September 28, 2006	
*				First Named Inventor	OHARA et al.	
STATEMENT BY APPLICANT			ANI	Art Unit	xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx	
(Use as many sheets as necessary)				Examiner Name	**************************************	
Sheet	2	of	2	Attorney Docket Number	3190-100	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		International Preliminary Report on Patentability and Written Opinion for PCT/JP/2005/005918 dated October 26, 2006	
		HART et al., Cellular Transformation and Guanine Nucleotide Exchange Activity Are Catalyzed by a Common Domain on the <i>dbl</i> Oncogene Product," THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 269, No. 1, January 7, 1994, pp. 62-65.	
		BI et al., "Autoinhibition Mechanism of Proto-DbI," MOLECULAR AND CELLULAR BIOLOGY, Vol. 21, No. 5, March 2001, pp. 1463-1474.	
Na		KATZAV et al., "VAV, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells," THE EMBO JOURNAL, Vol. 8, No. 8, 1989, pp. 2283-2290	
		COSTELLO et al., "The Rho-family GTP exchange factor Vav is a critical transducer of T cell receptor signals to the calcium, ERK, and NF-kB pathways," PROC. NATL. ACAD, SCI. USA, Vol. 96, March 1999, pp. 3035-3040.	
		HORII et al., "A novel oncogene, <i>ost</i> , encodes a guanine nucleotide exchange factor that potentially links Rho and Rac signaling pathways," THE EMBO JOURNAL, Vol. 13, No. 20, 1994, pp. 4776-4786	
		TOKSOZ et al., "Novel human oncogene LBC detected by transfection with distinct homology regions to signal transduction products," ONCOGENE, No. 9, 1994, pp. 621-628.	
		O'BRIEN et al., "Skeletal muscle deformity and neuronal disorder in Trio exchange factor-deficient mouse embryos," PNAS, Vol. 97, No. 22, October 24, 2000, pp. 12074-12078.	
		PENZES et al., "Distinct Roles for the Two Rho GDP/GTP Exchange Factor Domains of Kalirin in Regulation of Neurite Growth and Neuronal Morphology," THE JOURNAL OF NEUROSCIENCE, Vol. 21(21), November 1, 2001, pp. 8426-8434.	
		OHARA et al., "Construction and Characterization of Human Brain cDNA Libraries Suitable for Analysis of cDNA Clones Encoding Relatively Large Proteins," DNA RESEARCH, 4, 1997, pp. 53-59.	

Examiner	/Anand Desai/	Date
Signature	/Alianu Desal/	Considered 10/03/2008

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.